K. Schalk

发表

Non‐invasive quantitation of liver iron‐overload by magnetic resonance imaging

R. Gottschalk, J. Kaltwasser, K. Schalk, 1990, British journal of haematology.

The 10.000/μl Morning Trigger for Prophylactic Platelet Transfusion is Safe: Prospective Experience in 411 AML Patients

K. Wilms, G. Ehninger, M. Gramatzki, 2001 .

Clinical trial on the effect of regular tea drinking on iron accumulation in genetic haemochromatosis

R. Gottschalk, C. Seidl, J. Kaltwasser, 1998, Gut.

Chemotherapy of Hodgkin’s lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group

V. Diehl, H. Gerhartz, W. Wilmanns, 1989, Medical oncology and tumor pharmacotherapy.

[Lung changes caused by Mycobacterium xenopi infection in a patient with bone marrow transplantation: problems in differential diagnosis].

S. Rüsch-Gerdes, G. Ehninger, R. Dierkesmann, 1991, Pneumologie.

Juvenile idiopathic haemochromatosis: A life-threatening disorder presenting as hypogonadotropic hypogonadism

M. Cazzola, E. Ascari, G. Barosi, 2004, Human Genetics.

Juvenile Hemochromatosis

K. Schalk, E. Werner, J. Kaltwasser, 1988 .

Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.

M. Hansmann, L. Bergmann, H. Ritzel, 2002, European journal of cancer.

Cyclic alternating chemotherapy of high-grade malignant non-Hodgkin lymphomas with VIM-Bleo and CHOP.

K. Bross, C. Manegold, E. Heidemann, 1992, European journal of cancer.

Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's Lymphoma Study Group Trial HD5.

R. Greil, V. Diehl, J. Franklin, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of androgens on the response to antithymocyte globulin in patients with aplastic anaemia

K. Schalk, J. Kaltwasser, H. Vogt, 1988, European journal of haematology.

Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy: a study of the German Hodgkin's Lymphoma Study Group.

V. Diehl, N. Schmitz, J. Franklin, 1998, Blood.

Scientific Proceedings Second International Symposium on Cytostatic Drug Resistance

R. Pieters, K. Sikora, W. Siegert, 1991, Journal of Cancer Research and Clinical Oncology.

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line Treatment of Patients with Indolent and Mantle Cell Lymphomas - First Interim Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

M. Stauch, W. Brugger, N. Niederle, 2007 .

Bendamustine and rituximab (BR) are effective in the treatment of relapsed or refractory indolent and mantle-cell lymphomas: Long-term follow-up of a phase II study

N. Niederle, W. Knauf, M. Welslau, 2007 .

Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's Lymphoma Study Group HD6 trial.

R. Greil, N. Willich, V. Diehl, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease

V. Diehl, H. Gerhartz, K. Hübner, 1998 .